Literature DB >> 10761326

Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A.

K M Diab1, M M Zaki.   

Abstract

OBJECTIVE: To evaluate the long-term intake of Norplant, depot medroxyprogesterone acetate (DMPA) and low dose oral contraceptive pill (OCs) on glycemic control, lipoprotein metabolism and coagulation profile in diabetic women.
METHODS: Prospective comparative study including 80 uncomplicated controlled diabetic women. Twenty women allocated to each group. Clinical, metabolic and coagulation status were followed up at 3, 6 and 9 months' visits.
RESULTS: Fasting blood sugar increased in OCs and DMPA users. Total cholesterol (TC) and LDL-cholesterol (LDL-C) decreased in all groups except DMPA where it increased. Triglyceride (TG) only increased in OCs group. HDL-cholesterol (HDL-C) increased with OCs and decreased with Norplant and DMPA. Compared to IUD users, significantly higher percentage TG and HDL-C and lower LDL-C were observed in OCs users, while DMPA users had significantly higher TC and LDL-C and lower HDL-C. Partial thromboplastin time was prolonged in Norplant users.
CONCLUSION: In diabetics, Norplant results in minimal metabolic alterations followed by OCs while DMPA has unfavorable outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761326     DOI: 10.1111/j.1447-0756.2000.tb01195.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  11 in total

1.  Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.

Authors:  Emmanuelle Le Moigne; Cecile Tromeur; Aurelien Delluc; Maelenn Gouillou; Zarrin Alavi; Karine Lacut; Dominique Mottier; Gregoire Le Gal
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

Review 2.  Contraception in women with medical problems.

Authors:  Mandish K Dhanjal
Journal:  Obstet Med       Date:  2008-12-01

Review 3.  Putting risk into perspective: the US medical eligibility criteria for contraceptive use.

Authors:  Kathryn M Curtis; Naomi K Tepper; Polly A Marchbanks
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 4.  Contraception for Adolescents and Young Women with Type 2 Diabetes-Specific Considerations.

Authors:  Paulina M Merino; Ethel Codner
Journal:  Curr Diab Rep       Date:  2022-02-12       Impact factor: 4.810

5.  Pregestational Diabetes and Family Planning.

Authors:  Brittany N Hart; Jay H Shubrook; Tina Mason
Journal:  Clin Diabetes       Date:  2021-07

6.  Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus.

Authors:  Janet K Snell-Bergeon; Dana Dabelea; Lorraine G Ogden; John E Hokanson; Gregory L Kinney; James Ehrlich; Marian Rewers
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

7.  How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women?

Authors:  Hind A Beydoun; May A Beydoun; Hala Tamim
Journal:  Contraception       Date:  2008-12-11       Impact factor: 3.375

Review 8.  Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Authors:  Irving Sivin
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  The Intrauterine Device in Women with Diabetes Mellitus Type I and II: A Systematic Review.

Authors:  Norman D Goldstuck; Petrus S Steyn
Journal:  ISRN Obstet Gynecol       Date:  2013-12-11

10.  Association between contraceptive use and gestational diabetes: Missouri Pregnancy Risk Assessment Monitoring System, 2007-2008.

Authors:  Brittney A Kramer; Jeremy Kintzel; Venkata Garikapaty
Journal:  Prev Chronic Dis       Date:  2014-07-17       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.